Cell and gene therapy is an intricate mosaic-each innovation, each solution, each insight a vital piece of a greater whole. At Revvity, we bring these pieces together to help scientists, developers, and manufacturers compose their own breakthroughs. From discovery to pre-clinical, our broad solution-based ecosystem is designed to provide you with precision, scalability, and support regulatory compliance. Whether implementing base editing, optimizing vector design and production, or ensuring the quality of each step, Revvity solutions help transform vision into reality-piece by piece.
Explore how our portfolio supports in vivo, ex vivo, and cell therapy approaches
- Discover enabling technologies like Pin-point™ base editing, LentiBOOST™ transduction enhancer, LabChip™, and GMP-grade Cell-Vive™ reagents
- See how we help bridge the gap from discovery to delivery with tailored support across all five CGT development stages
- Meet our experts, learn about our solutions-based approach, and discover how Revvity can help you find the right piece for the quilt of your next therapeutic journey.
What's new
Cell-Vive™ GMP MojoSort™ Streptavidin Nanobeads
This column-free, magnetic bead-based system uses high-affinity biotin-conjugated antibodies for positive or negative selection of targeted cells. Our GMP Streptavidin Nanobeads boast low endotoxin levels and are manufactured under animal component-free conditions.
HostDetect™ HEK293 PCR DNA Quant Kit
This real-time PCR assay (RUO) enables quantitative detection of residual HEK293 host genomic DNA in extracted nucleic acid samples from biopharmaceutical products.
LabChip Plasmid DNA (pDNA) Assay
The LabChip™ Plasmid DNA assay is designed to streamline your plasmid (pDNA) workflows. It separates the three primary isoforms of pDNA in under 2 minutes/sample while providing purity assessment based on the corrected area percentages for each conformation.
Featured technologies
Pin-point™ Base Editing Platform
Transformative technology enabling single nucleotide changes without double-strand DNA breaks, for precision and reduced off-target effects.
Highly effective transduction enhancer for research and clinical application of lentiviral vectors in a wide range of cell types.
BioLegend’s Cell-Vive™ Portfolio
Serum-free, GMP-certified reagents designed for ex vivo cell processing and downstream manufacturing.
Cell Counting & Image Cytometry Instruments
Automated systems for accurate cell health, viability, and immunophenotyping assessments.
Cell and Gene Therapy Research Reagents
A range of discovery and bioanalytical immunoassays for the development and research of CGT therapies.
Advancing your gene and cell therapies with novel gene delivery technologies
Optimize your gene therapy vectors with Revvity
Our CGT ecosystem – Built for your journey
Identifying and validating disease-relevant genetic targets while facilitating efficient screening, cell characterization, and early gene editing—without compromising data quality or speed.
Delivering therapeutic payloads efficiently into target cells—while minimizing toxicity, immune response, and variability across viral and non-viral systems.
Bridging the gap between discovery and clinical trials requires robust tools to assess viability, expression, toxicity, and mechanism of action—across increasingly complex 3D models and in vivo systems.
Moving from small-scale experiments to clinical-grade production requires optimized processes, GMP-aligned reagents, and consistent vector performance—all while maintaining speed and regulatory readiness.
Helping every batch to meet regulatory expectations for identity, purity, potency, and stability—while streamlining testing workflows and reducing delays.
Our CGT ecosystem – Tailored for your therapy type
In vivo gene therapy delivers genetic material directly into the patient’s cells—typically using viral vectors such as AAV or lipid nanoparticles. These therapies are often designed for long-term or permanent correction with a single administration.
Ex vivo gene therapy involves harvesting a patient’s cells, genetically modifying them in vitro, and then re-infusing them. It facilitates tighter control over editing and characterization, often used in hematologic or immune-based therapies.
Cell therapy leverages the body’s natural cellular abilities to address complex health challenges, without altering the genetic makeup of the cells.
Meet us at ESGCT
Mosaic of Discovery: Revvity Science at ESGCT 2025
Each piece with purpose. Together, a CGT masterpiece.
At ESGCT 2025 in Seville, our scientists will present new data showing how the Pin-point™ base editing platform can help you transform gene editing. From safer hematopoietic stem cell editing to multiplexed CAR-T engineering and AI-designed deaminases, each study represents a tile in the mosaic of CGT innovation.
Safer editing for sensitive cell types – high-efficiency base editing in HSPCs with preserved stemness.
Streamlined cell therapy engineering – simultaneous knock-out and knock-in in a single step.
Next-generation precision – modular base editors tuned for accuracy, reduced off-target edits, and tailored therapeutic applications.
AI synergy – leveraging generative AI to design novel deaminases integrated into the Pin-point™ platform.
Posters
P0498: Accelerating allogeneic CAR-T cell generation: single-step complex engineering with the Pin-point™ platform and OpenCRISPR-1
Focus: One-step multiplexed knock-out and CAR transgene integration using RNA aptamer-mediated base editing; comparison of SpCas9 and AI-designed OpenCRISPR-1 nucleases.
Thursday 9 October from 14:00 to 15:30
P0514: Accelerating complex hypoimmunogenic stem cell engineering: a single-step process with the Pin-point™ platform
Focus: Simultaneous knock-out and knock-in in iPSCs, enabling generation of HLA-edited, hypoimmunogenic lines with retained pluripotency and immune evasion properties.
Thursday 9 October from 14:00 to 15:30
P0515: Development of precision base editors with the modular Pin-point™ platform
Focus: Modular plug-and-play assembly of Cas and deaminase components; scalable screening platforms for bespoke, high-fidelity base editor design.
Wednesday 8 October from 14:00 to 15:30
P0499: Efficient and safer base editing in HSPCs: avoiding DNA break pitfalls
Focus: High-efficiency editing (>80% at some sites) while maintaining stemness; superior safety compared to CRISPR-Cas9, enabling long-term therapeutic potential.
Wednesday 8 October from 14:00 to 15:30
P0517: Minimal activation of the p53 DNA damage response by modular base editors
Focus: Enhanced multiplexed editing efficiency in iPSCs with minimal DNA damage signaling, avoiding genome instability seen with nucleases.
Wednesday 8 October from 14:00 to 15:30
P0516: Simultaneous base editing with targeted transgene insertion using the Pin-point™ platform
Focus: Combined knock-out and knock-in in a single step across T cells and iPSCs; efficient integration into safe harbor and therapeutic loci.
Thursday 9 October from 14:00 to 15:30
P0476: Synergizing the Pin-point™ base editing platform with AI-designed adenine deaminases
Focus: Integration of five AI-designed deaminases; tailored editing precision and reduced off-target risk, highlighting AI + Pin-point synergy for next-gen base editors.
Thursday 9 October from 14:00 to 15:30
